VYGR - Voyager Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.34
+0.72 (+5.67%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close12.62
Open12.62
Bid0.00 x 1300
Ask0.00 x 1100
Day's Range12.50 - 13.49
52 Week Range6.26 - 28.38
Volume278,487
Avg. Volume334,011
Market Cap495.938M
Beta (5Y Monthly)1.93
PE Ratio (TTM)N/A
EPS (TTM)-1.11
Earnings DateMay 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.25
  • Hedge Funds Are Selling Voyager Therapeutics, Inc. (VYGR)
    Insider Monkey

    Hedge Funds Are Selling Voyager Therapeutics, Inc. (VYGR)

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

  • Neurocrine Adds to Pipeline With $2 Billion Takeda Deal
    GuruFocus.com

    Neurocrine Adds to Pipeline With $2 Billion Takeda Deal

    Biotech gets 7 drugs in partnership, 3 of which are in phase 2 testing Continue reading...

  • GlobeNewswire

    Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Voyager Therapeutics, Inc. (VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant of a non-qualified stock option and of restricted stock units as inducements material to her entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on June 15, 2020 and the restricted stock unit award is scheduled to become effective on July 1, 2020.

  • Barrons.com

    Gene-Therapy Treatments for Tay-Sachs, Sickle Cell, Other Diseases to Be Featured in Online Gathering

    This week’s online annual meeting of the American Society for Gene and Cell Therapy will take place on the web.

  • Analysts Are Betting On Voyager Therapeutics, Inc. (NASDAQ:VYGR) With A Big Upgrade This Week
    Simply Wall St.

    Analysts Are Betting On Voyager Therapeutics, Inc. (NASDAQ:VYGR) With A Big Upgrade This Week

    Celebrations may be in order for Voyager Therapeutics, Inc. (NASDAQ:VYGR) shareholders, with the analysts delivering a...

  • Should You Buy Voyager Therapeutics (VYGR) Ahead of Earnings?
    Zacks

    Should You Buy Voyager Therapeutics (VYGR) Ahead of Earnings?

    Voyager Therapeutics (VYGR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • GlobeNewswire

    Voyager Therapeutics Announces First Quarter 2020 Financial Results and Corporate Updates

    Voyager Therapeutics, Inc. (VYGR) today reported its first quarter 2020 financial results, program progress and corporate updates. “Our goal is to develop life-changing therapies for people living with severe neurological disease, and despite the ongoing COVID-19 health crisis, we ended the first quarter of 2020 in a strong position and expect to provide important progress updates across our programs over the course of 2020,” said Andre Turenne, President and Chief Executive Officer of Voyager. The protocol of the RESTORE-1 clinical trial of VY-AADC (NBIb-1817) for Parkinson’s disease is being amended to make the previously announced protocol modifications.

  • GlobeNewswire

    Voyager Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy Virtual 2020 Annual Meeting

    CAMBRIDGE, Mass., April 29, 2020 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.

  • 'You've got to do what you've got to do': Biotech workers assist with COVID-19 response
    American City Business Journals

    'You've got to do what you've got to do': Biotech workers assist with COVID-19 response

    Years before Cynthia Cassandro joined Cambridge biotech Voyager Therapeutics, she was a nurse working with AIDS patients in New York City. Since late March, she has been volunteering with the Medical Reserve Corps and Rhode Island’s Disaster Medical Assistance Team, screening entrants at an emergency response command center in Rhode Island for signs and symptoms of the virus. Each time she's volunteered, she's risked being exposed to the virus. "I couldn’t imagine knowing that I could do it, but not doing it,” Cassandro told the Business Journal. The life sciences industry is full of trained doctors, nurses, respiratory therapists, lab technicians and others who may be slightly rusty, but are ready to step in and help at overextended hospitals, care facilities or new medical centers that are being opened up across the state.

  • GlobeNewswire

    Voyager Therapeutics Provides Update on the RESTORE-1 Parkinson’s Disease Trial

    CAMBRIDGE, Mass., April 03, 2020 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.

  • Thomson Reuters StreetEvents

    Edited Transcript of VYGR earnings conference call or presentation 3-Mar-20 9:30pm GMT

    Q4 2019 Voyager Therapeutics Inc Earnings Call

  • GlobeNewswire

    Voyager Therapeutics Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference

    CAMBRIDGE, Mass., March 09, 2020 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR) announced today the cancellation of the Company’s presentation and webcast at the Barclays Global.

  • The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies
    Benzinga

    The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 3) * Acceleron Pharma Inc (NASDAQ: XLRN) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) * Fate Therapeutics Inc (NASDAQ: FATE) (reacted to its fourth-quarter results) * Forty Seven Inc (NASDAQ: FTSV) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO)( announced an accelerated timeline for COVID-19 vaccine development) * Repro-Med Systems, Inc. (NASDAQ: KRMD) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 3) * ADDEX THERAPEUT/ADR (NASDAQ: ADXN) * Akorn, Inc. (NASDAQ: AKRX) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * ANI Pharmaceuticals Inc (NASDAQ: ANIP) * Evolus Inc (NASDAQ: EOLS) * EXACT Sciences Corporation (NASDAQ: EXAS) * HTG Molecular Diagnostics Inc (NASDAQ: HTGM) * Midatech Pharma PLC-ADR (NASDAQ: MTP)(began trading on a reverse split adjusted basis) * Mylan NV (NASDAQ: MYL) * Neuronetics Inc (NASDAQ: STIM)(announced its fourth-quarter results) * Passage Bio Inc (NASDAQ: PASG)(IPOed last week) * STRATA Skin Sciences Inc (NASDAQ: SSKN) * SurModics, Inc. (NASDAQ: SRDX) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TransMedics Group Inc (NASDAQ: TMDX)(reported its fourth-quarter results) * VIVUS, Inc. (NASDAQ: VVUS) * Xeris Pharmaceuticals Inc (NASDAQ: XERS)See Also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA DatesStocks In Focus Takeda To Develop COVID-19 Treatments Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin to treat high-risk individuals with the viral infection. Hyperimmune globulins are plasma-derived therapies that had previously proven its efficacy in treating severe acute viral respiratory infections.The company added it is also studying its currently marketed and pipeline products to see whether they are effective treatments for infected patients.Separately, the company said it has completed its previously announced sale of portfolio of select products to STADA for $660 million.In pre-market trading Wednesday, Takeda shares were adding 3.94% to $18.20.Vir, Alnylam Expands Collaboration To Develop siRNA Therapies For COVID-19 Vir Biotechnology Inc (NASDAQ: VIR) and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced an expansion to their existing collaboration to include the development and commercialization of RNAi therapeutics against COVID-19. The agreement provides for Vir using Alnylam's recent advances in lung delivery of novel conjugates of siRNA along with its infectious disease expertise to develop one or some siRNAs to treat COVID-19 and other coronaviruses as well.In premarket trading Wednesday, Vir share were rallying 14.72% to $47 and Alnylam was edging up 0.41% to $111.88.Mallinckrodt Reports Positive Outcome Analysis of Acthar Gel In Immune-mediated Diseases Mallinckrodt PLC (NYSE: MNK) announced findings from a retrospective medical record analysis, which assessed practice patterns and outcomes of Acthar Gel in the treatment of immune-mediated diseases rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis/polymyositis, which showed across all the three patient populations, symptoms improved with Acthar Gel.In premarket trading Wednesday, the shares were advancing 7.99% $3.38.Acadia's Rett Syndrome Investigational Drug Gets Rare Pediatric Designation ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharma said the FDA has granted Rare Pediatric Disease designation to trofinetide for the treatment of Rett syndrome, a serious and rare neurological disorder.Upon approval of a product with the designation, the sponsor is eligible to receive a Priority Review Voucher, which can be used to obtain FDA approval of an NDA for another product in an expedited period of six months.Acadia shares were up 2.41% to $42.99 in after-hours trading.Morphosys' Licensing Agreement With Incyte For Lymphoma Drug Gets Antitrust Clearance Morphosys Ag (NASDAQ: MOR) and Incyte Corporation (NASDAQ: INCY) said their joint collaboration and license agreement for further development and global commercialization of Morphosys' investigational compound tafasitamab has received antitrust clearance and becomes effective Tuesday.The regulatory milestone triggers a $750 million upfront payment by Incyte to Morphosys, and also Incyte's equity investment of $150 million into MorphoSys within the defined timelines.The PDUFA date for the BLA for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma is Aug. 30.Ultragenyx CFO To Step Down Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) said Shalini Sharp will step down as CFO and EVP, effective Sept. 2. The company said it will initiate a search for a successor.Exact Sciences Buys Two Cancer Diagnostics Companies Exact Sciences said it has completed its acquisition of Paradigm Diagnostics and Viomics, two privately held companies, which provide a differentiated late-stage therapy selection test and deep competencies in sequencing and biomarker discovery.View more earnings on TAKThe company expects the acquisition to extend its lab testing and research and development capabilities.J&J Makes Regulatory Submission For Approval of Multiple Sclerosis Drug In Europe Johnson & Johnson's (NYSE: JNJ) Janssen unit announced it submitted a Marketing Authorization Application to EMA, seeking approval for ponesimod for the treatment of adult patients with relapsing multiple sclerosis.Earnings DURECT Corporation (NASDAQ: DRRX) reported fourth-quarter net revenues of $10.69 million compared to $3.63 million last year. The net loss per share narrowed from 5 cents to 2 cents, in line with the consensus estimate.The stock jumped 12.21% to $1.93 in after-hours trading.Menlo Therapeutics Inc's (NASDAQ: MNLO), which has agreed to be bought by Foamix Pharmaceuticals Ltd (NASDAQ: FOMX), reported a wider loss of 89 cents per share compared to the year-ago loss of 76 cents per share and the consensus loss estimate of 83 cents per share.Updating on the pending merger, Menlo said it expects it to close March 9.The stock jumped 23.64% to $3.40 in after-hours trading.Voyager Therapeutics Inc (NASDAQ: VYGR) reported fourth quarter revenues of $32.67 million compared to $2.01 million a year ago. The net loss per share narrowed from 77 cents to 34 cents. Analysts had estimated a loss of 81 cents per share. The company said it expects its cash reserves as well as receivables to be sufficient to meet its projected operating expenses and capex into mid-2022.The stock gained 6.22% to $12.30 in after-hours trading.Vivus reported fourth-quarter total revenues of $17.25 million and a loss of 61 cents per share, narrower than the 68 cents per share loss expected by analysts.The stock rose 8.98% to $1.82 in after-hours trading.Offerings Zogenix, Inc. (NASDAQ: ZGNX) said it has priced its underwritten public offering of 8.52 million shares at $23.50 per share. The company expects to raise gross proceeds of $200.2 million from the offering. The offering is expected to close on or about March 6.The company said it expects to use the net proceeds for the potential commercialization of Fintepla for the treatment of Dravet syndrome, among other things.The stock fell 3.69% to $24 in after-hours trading.On The Radar Earnings * AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (before the market open) * Recro Pharma Inc (NASDAQ: REPH) (before the market open) * PPD Inc (NASDAQ: PPD) (before the market open) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) (after the close) * Orthopediatrics Corp (NASDAQ: KIDS) (after the close) * Opiant Pharmaceuticals Inc (NASDAQ: OPNT) (after the close)See more from Benzinga * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More * The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Voyager Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates

    Protocol amendment being implemented for ongoing RESTORE-1 trial of VY-AADC (NBIb-1817) for Parkinson’s disease; plan to initiate RESTORE-2 trial in 2H 2020 Update on VY-HTT01.

  • GlobeNewswire

    Voyager Therapeutics to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Feb. 26, 2020 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.

  • GlobeNewswire

    Voyager Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 3, 2020

    CAMBRIDGE, Mass., Feb. 25, 2020 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.

  • Can You Imagine How Voyager Therapeutics's (NASDAQ:VYGR) Shareholders Feel About The 52% Share Price Increase?
    Simply Wall St.

    Can You Imagine How Voyager Therapeutics's (NASDAQ:VYGR) Shareholders Feel About The 52% Share Price Increase?

    Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...

  • Atlas, MPM, Partners funnel $49M into a new gene-silencing startup
    American City Business Journals

    Atlas, MPM, Partners funnel $49M into a new gene-silencing startup

    Two of the industry’s leading gene-editing experts have unveiled their next venture: a gene-silencing startup called Triplet Therapeutics.

  • Is Voyager Therapeutics, Inc. (VYGR) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is Voyager Therapeutics, Inc. (VYGR) Going To Burn These Hedge Funds ?

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • Thomson Reuters StreetEvents

    Edited Transcript of VYGR earnings conference call or presentation 6-Nov-19 1:00pm GMT

    Q3 2019 Voyager Therapeutics Inc Earnings Call

  • Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates
    Zacks

    Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates

    Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 50.60% and 419.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Voyager Therapeutics Announces Third Quarter 2019 Financial Results and Corporate Highlights

    CAMBRIDGE, Mass., Nov. 06, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.

  • GlobeNewswire

    Voyager Therapeutics to Present at the Credit Suisse Healthcare Conference

    CAMBRIDGE, Mass., Oct. 31, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.

  • GlobeNewswire

    Voyager Therapeutics to Host Third Quarter 2019 Financial Results and Corporate Highlights Conference Call

    CAMBRIDGE, Mass., Oct. 30, 2019 -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe.

  • Earnings Preview: Voyager Therapeutics (VYGR) Q3 Earnings Expected to Decline
    Zacks

    Earnings Preview: Voyager Therapeutics (VYGR) Q3 Earnings Expected to Decline

    Voyager Therapeutics (VYGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.